NCT00311753 - Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients | Biotech Hunter

Enrollment

342

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

December 31, 2007

Conditions

Embolism

Interventions

DRUG

Certoparin

Low-molecular-weight heparin, Certoparin (3000 U anti-Xa once daily) treatment period of 10 ± 2 days

DRUG

Heparin

7500 IU of unfractionated heparin administered twice daily during the treatment period of 10 ± 2 days

Trial Locations (2)

Investigative Centers

Novartis Pharmaceuticals, Basel